Compiled in 2011, Glenmark Life Sciences is a leading manufacturer of Active Pharmaceutical Ingredients (APIs). The company builds, manufactures, and provides high-quality APIs for heart disease (CVS), central nervous system (CNS), pain management, and diabetes, intestinal disorders, anti-infectives and other therapies. It continues to operate Contract Development and Manufacturing Services (CDMO) to provide services to specialized Pharmaceutical companies.
Its products are sold in India and exported to many countries namely Europe, North America, Latin America, Japan, etc. Currently, it has 4 production facilities in Ankleshwar and Dahej in Gujarat and Mohol and Kurkumbh in Maharashtra State annually with an installed capacity of 725.8 KL from December 31, 2020.
Competitive Strengths
- Leading manufacturer of selected specialized APIs for chronic therapeutic areas like CVS, CNS, diabetes, and pain management.
- Export products in Europe, Latin America, North America, Japan, and the rest of the world.
- Strong relationship with leading global generic companies.
- Proven track record of strong financial performance.
- High-quality product manufacturing with R&D infrastructure.
Company Promoters
Glenmark Pharmaceuticals Limited is the promoter of the company.
Company Financials
Particulars | For the year/period ended (₹ in million) | ||
---|---|---|---|
31-Mar-21 | 31-Mar-20 | 31-Mar-19 | |
Total Assets | 19,970.75 | 17,256.04 | 14,753.95 |
Total Revenue | 18,859.76 | 15,493.03 | 8,868.65 |
Profit After Tax | 3,515.81 | 3,130.98 | 1,955.92 |
Objects of the Issue
- To make payment of outstanding purchase consideration to the promoter for the spin-off of the API business from the promoter into the company.
- To finance capital expenditure requirements.
- To meet general corporate purposes.
Glenmark Life Sciences IPO – Details
IPO Opening Date | July 27, 2021 |
IPO Closing Date | July 29, 2021 |
Issue Type | Book Built Issue IPO |
Issue Size | 1000 Cr Fresh Issue + 450 Crore Offer For Sale |
Face Value | ₹2 per equity share |
IPO Price | [695] To [720] Per Equity Share |
Market Lot | 20 Shares |
Min Order Quantity | 20 Shares |
Listing At | BSE SME |
Total Share Issue | 63,00,000 Equity Shares |
Register | KFintech Private Limited |
Glenmark Life Sciences IPO – Timetable
IPO Open Date | Jul 27, 2021 |
IPO Close Date | Jul 29, 2021 |
Basis of Allotment Date | Aug 03, 2021 |
Initiation of Refunds | Aug 04, 2021 |
Credit of Shares to Demat Account | Aug 05, 2021 |
IPO Listing Date | Aug 06, 2021 |
Glenmark Life Sciences IPO Lots Size & Price
Application | Lots | Shares | Amount ( Cut-Off) |
Minimum | 1 | 20 | 14,400 |
Maximum | 13 | 260 | 1,87,200 |
Company Contact Information
Glenmark Life Sciences Limited Plot No. 170-172, Chandramouli Industrial Estate, Mohol Bazarpeth, Solapur 413 213, Phone: +91 2189 234456/ +91 2189 Email: complianceofficer@glenmarklifesciences.com Website: http://www.glenmarklifesciences.com/ |
Glenmark Life Sciences IPO FAQs
What is Glenmark Life Sciences IPO? Glenmark Life Sciences IPO is a main-board IPO of [.] equity shares of the face value of ₹2 aggregating up to ₹[.] Crores. The issue is priced at [.] to [.] per equity share. The minimum order quantity is . The IPO opens on Jul 27, 2021, and closes on Jul 29, 2021. KFintech Private Limited is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE. |
When Glenmark Life Sciences IPO will open? The Glenmark Life Sciences IPO opens on Jul 27, 2021 and closes on Jul 29, 2021. |
What is the lot size of Glenmark Life Sciences IPO? Glenmark Life Sciences IPO lot size is 20 Shares and the minimum order quantity is 20 Shares. |
How to apply for Glenmark Life Sciences IPO? You can apply in Glenmark Life Sciences IPO online using either UPI or ASBA as payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO application is offered by brokers who don’t offer banking services. |
When is Glenmark Life Sciences IPO listing date? The Glenmark Life Sciences IPO listing date is Announced. The date of Glenmark Life Sciences IPO listing is Jul 06, 2021. |